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Abstract
Background: Human herpesvirus-8 (HHV-8), the etiologic agent of Kaposi sarcoma (KS), establishes lifelong latent
infection with periodic lytic replication (“shedding”) at mucosal sites, especially the oropharynx. Patterns of HHV-8
shedding are not well understood, and require elucidation to better predict risk of HHV-8 related malignancies in
those infected. We sought to characterize patterns of HHV-8 oropharyngeal shedding among diverse cohorts that
enrolled HHV-8 seropositive persons.
Methods: We quantified HHV-8 oral shedding using PCR among HHV-8 seropositive persons who collected at least
14 days of oral swabs in 22 studies on 3 continents. We excluded persons taking antivirals during sampling or any
prior use of antiretrovirals in those who were HIV-infected.
Results: 248 participants were enrolled from the US, Peru, Cameroon, Uganda, and Kenya; 61 % were men, 58 %
were HIV seropositive, and 16 % had KS. Overall, 3,123 of 10,557 samples (29.6 %) had HHV-8 detected. Quantity of
virus shed was highly correlated with shedding rate, (ρ = 0.72, p < 0.0001). HHV-8 was detected in ≥1 sample in 55 %
of participants with a median of 7 % of days in the US and Kenya, 0 % in Uganda and Peru, and 18 % in Cameroon.
Median episode duration was three days, and episodes with high median quantity lasted longer (42 vs 3 days,
p < 0.0001). In persons with multiple observations over time, 66 % of shedding rate variance was attributable to
differences between individuals.
Conclusions: In HHV-8 infected individuals from diverse settings, oral mucosal shedding rate, quantity, and
duration were correlated; individual shedding was highly variable. Studies are needed to determine factors
accounting for between-person variation and the relationship of HHV-8 shedding to development of associated
diseases.
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Background
Human herpesvirus-8 (HHV-8), also known as Kaposi
sarcoma-associated herpesvirus (KSHV), establishes life-
long latent infection, punctuated with periods of lytic
replication at mucosal sites (“shedding”) [1]. Shedding is
most commonly detected at the oropharynx, which is
thought to be the site of transmission, primary HHV-8
latency and reactivation [2–4]. Prevalence of HHV-8 in-
fection is geographically variable, in >60 % of adults in
Uganda and other sub-Saharan African (SSA) countries
[5, 6] and as low as 3.3 % in healthy Americans [7, 8].
While in most people HHV-8 is asymptomatic, HHV-8
replication is considered to be integral to the develop-
ment and maintenance of Kaposi sarcoma (KS). Other
sequelae of the infection include Multicentric Castleman
Disease (MCD), Primary Effusion Lymphoma as well as
the recently described KHSV Inflammatory Cytokine
Syndrome [9–12].
Despite high seroprevalence of HHV-8 in many regions,
HHV-8 associated diseases are relatively uncommon, ex-
cept in the endemic regions of SSA, or in persons with ad-
vanced immunosuppression. KS remains the second most
prevalent cancer in men and the fifth most prevalent can-
cer in women in the WHO Africa region [13]. Previous
work by our group demonstrated that HHV-8 mucosal
shedding is associated with presence of KS and male sex,
but not with HIV infection [4]. Prior studies assessing oral
HHV-8 shedding evaluated small numbers of participants
and were limited in geography [14]. The patterns of HHV-
8 shedding, such as duration of shedding episodes, inter-
val between episodes, and variability between persons have
not yet been characterized. Due to the heterogeneity
of cohort composition, we describe shedding charac-
teristics and patterns across all persons, avoiding pre-
diction of shedding by geographic, demographic or
clinical covariates. We assembled diverse cohorts of
HHV-8 infected individuals to describe patterns of
HHV-8 oral mucosal shedding including rate, quan-




Between 1993 and 2011, 248 subjects met inclusion cri-
teria and contributed 298 sessions (observation periods)
to the primary analysis, with median duration of 30 days
(range 14–136) per session [Fig. 1]. These cohorts in-
cluded persons at high risk for HHV-8 infection, includ-
ing heterosexuals from KS-endemic regions, men who
have sex with men, and female sex workers. Overall, 152
(61 %) participants were men, and the median age was
38 (interquartile range, IQR: 31–45). One hundred forty-
three participants (58 %) were HIV-infected, 35 (14 %)
had KS, and 1 (0.4 %) had MCD. Among 143 persons
with HIV, CD4 count was <200 in 9 (6 %), 200–499 in
31 (22 %), ≥500 in 17 (12 %) and not available in 86
(60 %). HIV RNA was <104 copies/mL in 23 (16 %), and
unmeasured in 70 (49 %). Sixteen (44 %) had endemic
KS, and 20 (56 %) had HIV-associated KS. All partici-
pants from Peru and Cameroon were HIV-infected,
while other sites enrolled both HIV-infected and unin-
fected persons [Table 1 and Fig. 2].
Fig. 1 Flow diagram of study participant inclusion. Numbers listed are n = number of participants (“sessions” = number of observation periods
contributed). Abbreviations: ART, antiretroviral therapy; US: United States
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Table 1 Cohort, participant, and shedding characteristics
Participant Location, N (%)a USA Peru Cameroon Uganda Kenya Total
102 (41 %) 7 (3 %) 32 (13 %) 68 (27 %) 39 (16 %) 248 (100 %)
Participant Demographic and Clinical Data:
Male, n (%) 101 (99 %) 7 (100 %) 0 (0 %) 44 (65 %) 0 (0 %) 152 (61 %)
HIV-infected, n (%) 46 (46 %) 7 (100 %) 32 (100 %) 37 (54 %) 21 (54 %) 143 (58 %)
CD4 countb
CD4 < 200 9 (20 %) 0 (0 %) 0 (0 %) – – 9 (6 %)
CD4 200–499 17 (37 %) 1 (14 %) 13 (41 %) – – 31 (22 %)
CD4 500+ 12 (26 %) 0 (0 %) 5 (16 %) – – 17 (12 %)
Unknown 8 (17 %) 6 (86 %) 14 (44 %) 37 (100 %) 21 (100 %) 86 (60 %)
HIV-1 RNAb
<104 12 (26 %) 4 (57 %) – 7 (18 %) – 23 (16 %)
≥104 22 (48 %) 3 (43 %) – 25 (68 %) – 50 (35 %)
Unknown 12 (26 %) 0 (0 %) 32 (100 %) 5 (14 %) 21 (100 %) 70 (49 %)
Kaposi sarcoma: 2 (2 %) 0 (0 %) 0 (0 %) 34 (50 %) 0 (0 %) 36 (15 %)
HIV-associated: 1 (1 %) – – 19 (28 %) – 20 (8 %)
HSV-2 seropositive, n/tested (%) 62/97 (64 %) 7 (100 %) 31 (97 %) ND ND 100/135 (74 %)
Cohort Shedding Characteristics:
Sessions,
Number: 152 7 32 68 39 298
Observations per session:
Median # of days (range) 33 (15–136) 56 (27–57) 19 (14–23) 29 (14–32) 29 (26–29) 30 (14–136)
Overall shedding:
Positive swabs: 2,213 75 183 389 263 3,123
Total swabs: 6,660 359 590 1834 1,114 10,557
Percent positive: (33 %) (21 %) (31 %) (21 %) (24 %) (30 %)
Participant shedding rate per session,
Median % (IQR) 7 (0, 73) 0 (0, 33) 18 (0, 56) 0 (0, 34) 7 (0, 43) 4 (0, 54)
Persons with any shedding 60 (59 %) 3 (43 %) 21 (66 %) 26 (38 %) 27 (69 %) 137 (55 %)
Quantity, median (IQR) of positive swabs, log10 copies/mL 4.8 (3.9–5.6) 7.4 (5.0–7.8) 3.2 (2.7–3.8) 5.2 (3.9–6.0) 4.4 (3.5–5.5) 4.7 (3.7–5.6)
Abbreviations. US United States, ND Not determined, IQR Interquartile Range, HSV Herpes simplex virus
aPercentages are out of those within the given country
bPercentages for CD4 count and HIV RNA are of HIV-infected participants
Fig. 2 Heterogeneity of participant characteristics within the cohorts included in this study
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HHV-8 shedding rate and quantity
Overall, 10,557 swabs were analyzed for HHV-8 DNA,
and HHV-8 was detected in 3,123 (29.5 %). Within the
entire cohort, 137 persons (55 %) had HHV-8 DNA de-
tected at least once. The median (IQR) shedding rate
per session was 7 % (0–73 %) in the US, 0 % (0–33 %)
in Peru, 18 % (0–56 %) in Cameroon, 0 % (0–34 %) in
Uganda, 7 % (0–43 %) in Kenya, and 4 % (0–54 %)
overall [Table 1]. Among US participants, 33 % of
swabs had detectable HHV-8 DNA, 21 % in Peru, 31 %
in Cameroon, 21 % in Uganda and 24 % in Kenya
[Table 1]. In order to validate the utilization of samples
from persons with and without HIV and KS, we com-
pared shedding rate within the factorial design of the
Ugandan cohort as previously described [4]. In 34
Ugandan persons with KS, the shedding rate was 25 %
in HIV-associated cases and 40 % in endemic KS cases;
Ugandans without KS had a shedding rate of 27 %. The
Ugandan cohort was the only African cohort to include
both men and women; HHV-8 was detected in 30 % of
samples from men, compared with 6 % from women.
Amongst all cohorts, HHV-8 was detected in 18 % of
swabs from HIV-infected individuals and 18 % of swabs
from HIV-uninfected individuals.
The median quantity of HHV-8 DNA in samples with
HHV-8 detected was 4.7 (IQR: 3.7–5.6) log10 copies/
mL [Fig. 3]. Median HHV-8 quantity during the session
correlated strongly with shedding rate (ρ = 0.72, p < 0.0001)
[Fig. 4]. Maximum quantity of HHV-8 detected during a
session also correlated highly with the shedding rate (ρ =
0.82, p < 0.0001) (data not shown).
Shedding episodes
We defined a shedding episode as a period of detect-
able HHV-8 of at least one day bounded by at least two
preceding and subsequent negative swabs, and could
include singular missed or negative swabs [15]. When
initiation or termination of the shedding episode was
not observed, interval-censoring survival was used esti-
mate the episode duration. We dichotomized episodes
by median quantity above or below the median quantity
of all detectable samples and tested the association be-
tween quantity and duration for episodes with log rank
tests. We evaluated up to 3 shedding episodes per
session, for a total of 229 episodes in 116 persons.
Duration was uncertain in 106 (46 %) episodes because
of censoring at either limit of session observation. For
123 episodes of certain duration, the median duration
was 1 day (IQR: 1–4 days). Using interval censoring
survival analysis to include both episodes of certain and
uncertain duration, 30 % of episodes were predicted to
last less than 1 day, 50 % to last less than 9 days, and 60 %
to last less than 20 days. One hundred-nineteen episodes
(52 %) with a high median quantity (>4.5 log10 copies/mL)
had a predicted median duration of 42 days; for episodes
with lower median quantity (≤4.5 log10 copies/mL), the
median duration was 3 days (p < 0.0001). We investigated
the duration of shedding episodes and intervals without
HHV-8 shedding between episodes. “Short” episodes were
defined as ≤ 3 days (median duration of all episodes) and
“long” episodes as > 3 days. Short episodes were preceded
by a median 13-day interval without shedding whereas
long episodes were preceded by a median 7-day interval
(p = 0.035). A sensitivity analysis reclassifying episodes
censored prior to 3 days (26 episodes) as “short” instead of
“long” provided similar estimates.
To illustrate patterns of HHV-8 shedding, data from
participants who collected swabs for 30–60 days and who
shed at least once were included in a heatmap [Fig. 5]. We
did not observe a singular pattern of shedding, but rather
Fig. 3 Quantity of HHV-8 DNA (Log10 copies/mL) within swabs positive
for HHV-8. 2.17 Log10 copies/mL represents the lower limit of accurate
detection (150 copies/mL). The label for each bin represents a range
including the value listed and all values up to but not including the
value listed in the next highest bin
Fig. 4 Correlation of HHV-8 DNA quantity and shedding rate: Scatterplot
of HHV-8 quantity (median HHV-8 DNA copy number by qPCR during
shedding session) vs. HHV-8 shedding rate (number of days HHV-8 is
detectable at any level by qPCR divided by number of days of shedding
session). Best-fit regression line is shown (ρ= 0.72, p< 0.0001)
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a gradation was noted from infrequent and low copy num-
ber shedding to very frequent and high copy number
shedding. For example, some participants shed virus in
single-day episodes, while others had intermittent epi-
sodes of both high and low quantities, and a few partici-
pants shed virus at high quantities throughout the session.
Participants with KS and HIV were dispersed amongst
participants when sorted by shedding rate [Fig. 5].
Variation in shedding rate over time
Stability of shedding rate over time was evaluated in par-
ticipants contributing multiple sessions. Thirty-nine par-
ticipants, all of whom were from the United States, had at
least one additional session within two years of the first:
19 persons had 2, 9 persons had 3, 8 persons had 4, and 3
persons had 5, totaling 112 sessions. The median shedding
rate of first sessions was 50 %. Over time, 4 persons
(10.3 %) had shedding rate increase by at least 30 % on an
absolute scale, 7 persons (18.0 %) had shedding rate
decrease by the same amount, and 28 (71.8 %) had
no consistent pattern or a stable shedding rate [Fig. 6].
Using variance components, we examined the variation in
Fig. 5 Patterns of HHV-8 Shedding. Included participants had HHV-8 detectable by PCR on at least one day during the first 60 days of observation
and were observed for a minimum of 30 days. Each row represents one participant, ordered by shedding rate from lowest to highest over the
shedding session. Sixty participants with at least 30 days of observation who never shed were omitted. Time is represented on the x-axis (in days)
such that each box represents the HHV-8 PCR result from a single daily swab for an individual. DNA quantity is graded by color (in log10 copies/
mL). Asterisks (*) denote participants with Kaposi Sarcoma and plus signs (+) denote participants with HIV. White indicates no swab collected;
other colors as per legend
Fig. 6 Variation in oral shedding rate of HHV-8 by participant across
multiple shedding sessions. All cohort participants with 2–5 sessions
within two years were included in the analysis of shedding variation
over time, representing 39 participants with 112 total sessions. Four
persons had shedding rates increase by at least 30 % on an absolute
scale over time (red), 7 persons had rates decrease by the same
amount (blue), and 28 had no consistent pattern (black)
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shedding rates over time within the population that was
due to inter-person versus intra-person differences. We
found that 66 % of the variance was due to inter-person
differences and the remainder due to change in an individ-
ual’s shedding rate over multiple sessions.
Discussion
This is the largest study of HHV-8 shedding published
to date, evaluating more than 10,000 oral swab samples
collected from geographically and demographically di-
verse HHV-8 seropositive persons not receiving anti-
viral or antiretroviral therapy. HHV-8 shedding was a
common event, although nearly half of participants
never shed while under observation. We found a strong
correlation between shedding rate, quantity, and dur-
ation of oropharyngeal shedding within an individual,
but significant variability between individuals.
Our findings are consistent with earlier studies of
HHV-8 oropharyngeal shedding that observed 15 %-
32 % shedding rates [2, 16, 17]. In our large cohort, we
observed a gradation in shedding rate and quantity
across participants. In comparison to HSV-2, a herpes-
virus with well-characterized shedding patterns, we
found several differences in mucosal reactivation pat-
terns. HSV-2 reactivation is characterized by shorter
episodes with 20 % lasting >9 days [18], whereas we
found longer episodes of HHV-8 shedding, with 40 %
ongoing at 20 days. In contrast to HSV-2, which has
rapid expansion and decay, we observed variable pat-
terns of HHV-8 shedding, with many episodes showing
a long plateau without observed termination. Additionally,
quantity of HHV-8 detected tended to be more homoge-
neous compared to HSV-2, with the vast majority of
swabs clustered around 4.5 log copies/mL, whereas HSV-
2 is frequently detected at both lower and much higher
quantities [18, 19]. Our analysis found similar shedding
rates in HIV-infected and uninfected individuals, an intri-
guing finding that is dissimilar to other herpesviruses,
including HSV, CMV, and EBV [20–24].
HHV-8 shedding in relationship to KS and HIV has
been studied and results are inconsistent. In Uganda, KS
patients were more likely to have HHV-8 detected than
those with asymptomatic HHV-8 infection, while HIV ser-
ostatus was not associated with detection of HHV-8 in the
oral mucosa [4]. Another cross-sectional study found no
difference in detection of HHV-8 shedding in the oral mu-
cosa of HIV-infected men with and without KS [25];
persons with KS in our study were not observed prior to
onset of disease. Our data do not address the risk of
asymptomatically-infected persons developing HHV-8-
associated diseases, nor compare shedding patterns
between persons with HHV-8 related diseases and asymp-
tomatic infection; the understanding of viral shedding
patterns gained from our work may be used to design lon-
gitudinal studies to address questions of HHV-8 transmis-
sion and disease association.
Our study was limited by performance characteristics of
the HHV-8 serologic assays used to include and exclude
participants, which have sub-optimal sensitivity and speci-
ficity [26, 27]. We may have excluded persons from our
cohort who were HHV-8 infected but seronegative, or in-
cluded those with false positive serology. Using PCR to
quantitate oral virus may not strictly detect lytic replicat-
ing virus, as latent cell-associated virus may also be
present in these samples. However, that the large majority
of samples were negative in HHV-8 seropositive persons
suggests that latent virus in oral epithelial cells is generally
not detected by this collection method and PCR tech-
nique. Additionally, we were limited in our ability to
model demographic and clinical risk factors for HHV-8
shedding due to both measured and unmeasured co-
founders in these heterogeneous cohorts, especially with
respect to available HIV clinical data. Conversely, the di-
versity of participants in this large cohort allowed us to
describe HHV-8 shedding patterns unrestricted to any
narrow population or geographic area, as has frequently
been done up to this point. We benefitted from long ses-
sions and serial observations on many participants; prior
studies have not been able to evaluate viral replication pat-
terns in individuals over time. Other strengths of this
study include robust methods of swab collection, labora-
tory, and statistical analysis concordant with methods
used by our group in studies of herpesvirus shedding over
the last three decades. While different PCR methods were
used in our reference laboratory during the time period
over which our cohorts span, the standardization was
consistent across all cohorts, was supervised by the same
virologist, and quality control showed high correlation be-
tween assays.
Conclusions
We did not detect a consistent or singular pattern to
HHV-8 shedding, and substantial variability was observed
between persons. We demonstrated that rate and quantity
of HHV-8 shedding are highly correlated and that persons
experiencing longer and higher quantity shedding episodes
can be predicted to shed more frequently in the future.
Patterns of HHV-8 shedding are distinctly different from
other well-characterized herpesvirus infections, such as
HSV-2. This work provides a foundation to assess mucosal
shedding of HHV-8 as a possible biomarker to assess risk
of HHV-8 transmission or disease. Longitudinal studies in
asymptomatically infected persons are needed to further
understand clinical correlates to patterns of HHV-8 shed-
ding, and if replication is associated with HHV-8 related
diseases.
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Methods
We evaluated 22 prospective cohorts in which HHV-8
DNA quantification had been performed on oropharyn-
geal swabs, including 18 cohorts from the Virology
Research Clinic, University of Washington [14, 28–32],
and 4 studies by affiliated investigators in Lima, Peru
[33]; Kampala, Uganda [4]; Mombasa, Kenya [34]; and
Yaounde, Cameroon. The University of Washington In-
stitutional Review Board and appropriate partner insti-
tutions for international sites approved each study; all
participants provided written informed consent in ac-
cordance with the Declaration of Helsinki. Participants
collected daily samples of the oropharyngeal mucosa
with a Dacron swab (three times weekly in Cameroon
only) with similar technique across all studies, for a
minimum of 14 days [35]. Each such observation period
is termed a “session”. We included HHV-8 seropositive
adults (age ≥18) with and without HIV, and with and
without HHV-8 associated diseases including MCD and
KS. We included HIV-infected participants only if anti-
retroviral naïve to avoid confounding from immune
restoration and potential direct and indirect effects of
ART on HHV-8 replication [36]. We excluded partici-
pants receiving antiviral therapies including valganci-
clovir, acyclovir, valacyclovir or famciclovir [31], and
participants with ≤14 samples per session, as prior ana-
lyses performed by our group demonstrate substantial
instability in herpesvirus shedding estimates with fewer
samples [37]. Data from 216 of 298 HHV-8 shedding
sessions (72 %) included in this analysis were previously
published [1, 4, 14, 16, 31, 34, 38]. We aggregated per-
sons from these diverse populations to more robustly
describe associations between shedding rate, quantity,
duration, and variability of shedding episodes in HHV-
8 infected persons.
Laboratory methods
HHV-8 seropositivity was determined by positive test
result on either immunofluorescence assay (IFA)
against latent or lytic antibodies [39] or whole-virus en-
zyme immunoassay (EIA) [27]. Swabs were collected
into lysis buffer containing 100 mM KCl (or NaCl),
25 mM EDTA (pH 8.0), 10 mM Tris (pH 8.0), and 1 %
Igepal CA-630 and stored at −20 °C until testing, a process
validated to be stable for extended storage [40, 41]. Quan-
titative polymerase chain reaction (qPCR) was performed
to quantitate HHV-8 DNA using previously described and
validated methods [1, 16, 38, 42]. Three qPCR assays were
used using the study period: the KS330Bam233 region of
orf26 (a viral capsid protein)1, orf73 (latency-associated
nuclear antigen-1)2 or a multiplex assay using orf73 plus
T07-K12 (kaposin)3. Briefly, early samples (orf26 assay)
were extracted from swabs with traditional phenol-
chloroform method and all other samples were extracted
using Qiagen column (QIAmap DNA blood kit), then
purified, and amplified with the given primers-probe sets
on the Taqman qPCR platform (Applied Biosystems, Fos-
ter City, CA). Compared to qPCR with orf73 as the gold
standard, orf26 had sensitivity 83.1 %, specificity 98.8 %.
To minimize the variance in sensitivity at low end of de-
tectable range, a cut-off of ≥150 copies/mL (≥3 copies/
PCR reaction) were considered positive for HHV-8 detec-
tion [43]. Applying this cut-off, the correlation between
orf26 and orf73 results was R2 = 0.75. Compared to qPCR
with orf73 and T07-K12 multiplex as the gold standard,
orf73 had a sensitivity of 94.1 %, specificity of 97.5 %.
Applying the minimum cut-off for positivity, the correl-
ation between the latter two primer sets was R2 = 0.96.
Quantitation standard using the cloned PCR product of
KS330Bam233 primers was consistent throughout all co-
horts. Quality control using standardization and positive
and negative controls for each batch were supervised by
M.L.H. in the same Seattle-based reference laboratory for
all cohorts. Overall, 92 % of samples were run with the
orf73 assay, 5 % with the orf26 assay and 3 % with the
orf73 and T07.K12 multiplex assay.
Statistical analysis
Sessions are defined as discrete periods of contiguous
swab collection ≥14 days and separated in time from other
observation periods. For participants contributing mul-
tiple sessions, the first and second sessions were included
in the primary analysis. For each session, shedding rate
was defined as number of swabs with HHV-8 DNA detec-
tion, divided by total swabs. Quantity of HHV-8 was log10
transformed for analysis and was assessed as maximum
and median log10 copies/mL. We used Pearson correla-
tions to evaluate the association of shedding rate with
maximum and median log10 copy number within sessions.
To test the association of episode duration with time
between episodes, we classified episodes as “short” or
“long” by dichotomizing at the median length of all epi-
sodes and used log rank tests. First, we assumed epi-
sodes not observed to terminate were “long” and then
then performed a sensitivity analysis reclassifying these
episodes as “short”. We excluded Cameroonian samples
from episode duration analysis since swabbing was not
conducted daily.
Participants with two to five sessions were included in
the longitudinal shedding analysis. The proportion of
variability in shedding rate ascribed to the individual
was evaluated with variance components.
Endnotes
1ORF26-F: 5’- AGC CGA AAG GAT TCC ACC AT-3’,
ORF26-probe: ATG TGG TAC ACC AAC AGC TGC
TGC, ORF26-R: 5’- TCC GTG TTG TCT ACG TCC
AG-3’.
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2ORF73-F: 5'-CCA GGA AGT CCC ACA GTG TTC-
3', ORF73-probe: FAM-CAT CCG GGC TGC CAG
CAT TTG-TAMRA, ORF73-R: 5'-GCC ACC GGT AAA
GTA GGA CTA GAC-3'.
3T07.K12-F: 5'-TCC CCC ACC GAG TGC TT-3',
T07.K12-probe: FAM-AAT GCG GAG AGG AAT G-
MGB, T07.K12-R: 5'-GCA CGC GGT GTC AAC CA-3'.
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